• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    罗

    罗斯维尔公园癌症研究所

    Roswell Park Cancer Institute
    EST. 1898
    5,659论文总数
    41万引用总数

    Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is currently the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".The Roswell Park campus, spread out in 15 separate buildings of approximately two million square feet, occupies 28 acres (11 ha) on the 100-acre (40 ha) Buffalo Niagara Medical Campus (BNMC) in downtown Buffalo, and includes 1,500,000 square feet (140,000 m2) of space equally distributed between clinical programs and research/education functions. A separate hospital building, completed in 1998, houses a diagnostic and treatment center. The campus also includes a medical research complex as well as research and education focused spaces.

    论文量&引用量时间轴

    机构学者

    论文(5659)

    年份
    起
    –
    止
    排序
    1Transformation of the Tobacco Product Market in Japan, 2011-2023
    K Michael Cummings,Avery Roberson,David T Levy,Rafael Meza,Kenneth E Warner,Geoffrey T Fong,Steve Shaowei Xu,Shannon Gravely,Bibha Dhungel,Ron Borland,Richard J O'Connor,Maciej Lukasz Goniewicz,

    Objective This study updates a previous paper that examined trends in the sale of cigarettes and heated tobacco products (HTPs) in Japan between 2011 and part way through 2019. The current study includes complete unit sales data through 2023.Methods Data on cigarette and HTP sales were obtained from public sources available from the websites and stockholder reports for the Tobacco Institute of Japan, Philip Morris International and Japan Tobacco. We used joinpoint regression using the parametric method to test for trends in both per capita and total sales for the three outcome variables assessed between 2011 and 2023: (1) cigarette sales, (2) HTP sales and (3) combined cigarette and HTP sales. Joinpoint regression identifies changes in trends and estimates the annual per cent change (APC) for each trend segment.Results Between 2011 and 2023, per capita and total cigarette sales declined by 52.6% and 52.7%, respectively. From 2011 to 2015, per capita cigarette sales in Japan decreased -1.5% APC; from 2015 to 2018, the decline accelerated to -10.5% APC and continued to fall -7.3% APC between 2018 and 2023. Between 2016 and 2018, per capita HTP sales increased by 149.0% APC, and since 2018, they have increased by 8.1% APC.Conclusion While many factors may account for the decreased sale of cigarettes in Japan over the past 12 years, the increased sale of HTPs appears to be a factor.

    2026Tobacco control(2026)引用:5
    引用
    AI阅读
    加入学术空间
    2Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase.
    Yang Bai, Albert S Agustinus,Shira Yomtoubian,Cem Meydan, Dylan R McNally,Liron Yoffe,Melissa J Hubisz, Marvel Tranquille, Sneha Pramod,Christy Hong, Magdalena L Plasilova, Aakanksha R Kapoor,

    Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. Here, we uncover a direct role for EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer. Across breast cancers, EZH2 expression correlates with copy-number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacologic EZH2 inhibition suppresses CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified tankyrase (TNKS), a PARP, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts centrosomal P4.1-associated protein (CPAP), driving centrosome overduplication, multipolar mitosis, and exacerbated CIN. In vivo, CIN suppression is a critical mechanism underlying the antimetastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints. SIGNIFICANCE:We elucidate epigenetic regulation of CIN through EZH2-TNKS-CPAP-axis and show that CIN suppression is important for the efficacy of EZH2 inhibition on metastasis. These mechanistic insights are informative for developing CIN-suppressing therapies.

    2026Cancer discovery(2026)引用:3
    引用
    AI阅读
    加入学术空间
    3High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer.
    Luke Rodriguez,Rongrong Wu, Anelia Kassi,Takashi Ishikawa,Kazuaki Takabe

    BACKGROUND:Various poly(ADP-ribose) polymerases (PARPs) are known to be related to DNA repair, and PARP7 has been linked to estrogen signaling and immunity. Recently, PARP7 was shown to increase cancer cell proliferation, but reports are conflicting. Given that these studies are mostly based on in vitro experiments, this study investigated how PARP7 expression impacts breast cancer patients. METHODS:Clinical and transcriptomic data of breast cancer patients were obtained from the METABRIC (n = 1904), TCGA (n = 1090), and SCAN-B (n = 3069) cohorts. The median value was used to divide the cohorts into high- and low-PARP7 groups. RESULTS:High PARP7 expression was significantly associated with better overall survival in two of the three cohorts (p < 0.05), and PARP7 was expressed predominantly by epithelial cells (p < 0.001). Estrogen receptor (ER)-positive breast cancer had a higher expression of PARP7 than other subtypes (p < 0.001). High PARP7 expression was associated with high estrogen and androgen response consistently in all cohorts. Tumors expressing higher PARP7 levels had significantly lower mutation rates, neoantigens, type 1 interferon (IFN-1), and immune cell infiltration in (p < 0.001). High PARP7 expression was associated with less enrichment of cell proliferation-related gene sets (E2F targets, G2M checkpoint, and MYC targets), in all cohorts. Higher PARP7 expression was associated with less cancer cell proliferation, lower tumor grade, and lower Ki67 (p < 0.001). CONCLUSION:High PARP7 expression is associated with estrogen and androgen response, but also with better overall survival and lower cell proliferation.

    2026Annals of Surgical Oncology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    4A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked.
    Wei Zhao,Tongwu Zhang,Xing Hua,Phuc H Hoang, Mona Miraftab, Monjoy Saha, John P McElderry,Jian Sang, Olivia W Lee, Caleb Hartman,Azhar Khandekar, Sunandini Sharma,

    Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA sequencing data from 684 NS-LUAD cases and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and cell compositions. Additional genomic and histologic data further characterized the subtypes. "Steady," marked by low proliferation, high alveolar cell fraction, moderate-to-well differentiation, and fewer driver gene alterations, is linked to prolonged survival and low immune evasion. "Proliferative" shows high proliferation markers, TP53 mutations, and gene fusions. "Chaotic," with high epithelial-to-mesenchymal transition markers, has the worst prognosis, even within stage I tumors. Lacking known molecular or histologic characteristics, this aggressive subtype is solely identified by transcriptomic data. A 60-gene signature recapitulates the classification and predicts survival even within subgroups based on tumor stage or known genomic features, emphasizing its potential for improving early-stage NS-LUAD prognostication in clinical settings. SIGNIFICANCE:The transcriptome of 684 NS-LUAD identifies three subtypes with different cellular dynamics and genomic and morphologic features. A 60-gene signature accurately stratifies subjects for mortality risk, even in stage I, offering a potential clinically applicable tool for treatment decision-making in patients with NS-LUAD. See related commentary by Azizi et al., p. 423.

    2026Cancer discovery(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Nivolumab Plus Ipilimumab Versus Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma: Final Analysis of Efficacy and Safety from the Phase III CheckMate 214 Trial.
    T K Choueiri, L Albigès, D F McDermott, H J Hammers, B Escudier, M Burotto, E R Plimack, C Porta, S George, T Powles, F Donskov, M B Atkins,

    BACKGROUND:Nivolumab plus ipilimumab (NIVO + IPI) demonstrated significant long-term survival and response benefits in patients with previously untreated advanced renal cell carcinoma (aRCC) in the phase III CheckMate 214 trial (NCT02231749). We report final efficacy and safety results with 9.3 years median follow-up. PATIENTS AND METHODS:Patients (N = 1096) were randomized to NIVO 3 mg/kg plus IPI 1 mg/kg every 3 weeks × four doses, followed by NIVO (3 mg/kg or 240 mg every 2 weeks or 480 mg every 4 weeks); or sunitinib (SUN) (50 mg) once daily (4 weeks on, 2 weeks off). ENDPOINTS:overall survival (OS), and independent radiology review committee-assessed progression-free survival and objective response rate in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate/poor-risk (primary), intention-to-treat (secondary), and IMDC favorable-risk (exploratory) patients. RESULTS:With a median (range) follow-up of 9.3 years (8.6-9.9 years), the hazard ratio (95% confidence interval) for OS with NIVO + IPI versus SUN was 0.71 (0.62-0.82) in intention-to-treat patients, 0.69 (0.59-0.81) in intermediate/poor-risk patients, and 0.80 (0.59-1.09) in favorable-risk patients; 108-month OS probabilities were 31.4% versus 19.5%, 30.2% versus 18.7%, and 35.3% versus 21.8%, respectively. Progression-free survival probabilities at 96 months were 22.7% versus 9.0% (intention-to-treat), 25.4% versus 8.5% (intermediate/poor risk), and 12.5% versus 11.3% (favorable risk). Probabilities of remaining in response at 96 months with NIVO + IPI versus SUN were 48.0% versus 19.0% (intention-to-treat), 50.0% versus 23.0% (intermediate/poor risk), and 36.0% versus not estimable (favorable risk). Incidence of any-grade (grade 3-4) treatment-related adverse events (AEs) was 94.1% (48.6%) with NIVO + IPI versus 97.6% (64.1%) with SUN. Exploratory post hoc analyses reported include descriptive analyses of OS by immune-mediated AE discontinuation status. CONCLUSIONS:In the longest phase III follow-up of a first-line checkpoint inhibitor combination in aRCC (>9 years), NIVO + IPI maintained a substantial survival benefit with durable responses versus SUN. Grade 3-4 treatment-related AEs were lower with NIVO + IPI versus SUN at 9 years. NIVO + IPI remains a first-line standard of care in aRCC.

    2026Annals of oncology official journal of the European Society for Medical Oncology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 5659 篇论文

    合作机构(100)

    布法罗大学合作论文 186
    俄亥俄州立大学合作论文 174
    纪念斯隆凯特琳癌症中心合作论文 172
    布法罗大学,纽约州立大学合作论文 167
    温纳贝戈医学中心合作论文 167
    德克萨斯大学奥斯汀分校合作论文 153
    纽约州立大学合作论文 145
    华盛顿大学合作论文 144
    罗切斯特理工学院综合癌症中心合作论文 131
    国家癌症研究所合作论文 115

    机构统计